Optimizing the Clinical Pharmacology of Tuberculosis Medications

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 4, 2015, Pages 387-393

  Egelund, E F ^a,b   Alsultan, A ^a,b   Peloquin, C A ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAMANID; ETHAMBUTOL; ISONIAZID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; POSIZOLID; PRETOMANID; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; SUTEZOLID; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PHARMACOLOGY; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; TUBERCULOSIS; ANIMAL; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; MICROBIOLOGY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84948429686     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.180     Document Type: Article

References (75)

1. Crofton, J. The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line. J. R. Soc. Med. 99, 531-534 (2006).
2. Second East African/British Medical Research Council Study. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second Report. Am. Rev. Respir. Dis. 114, 471-375 (1976).
3. Hong Kong Chest Service, BMR Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tubercle. 60, 201-210 (1979).
4. Sahai, J. et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med. 127, 289-293 (1997).
5. Pasipanodya, J.G. et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis. 208, 1464-1473 (2013).
6. Heysell, S.K., Moore, J.L., Keller, S.J. & Houpt, E.R. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg. Infect. Dis. 16, 1546-1553 (2010).
7. Gumbo, T. et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51, 3781-3788 (2007).
8. Jayaram, R. et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47, 2118-2124 (2003).
9. Goutelle, S., Bourguignon, L., Maire, P., Jelliffe, R.W. & Neely, M.N. The case for using higher doses of first line anti-tuberculosis drugs to optimize efficacy. Curr. Pharm. Des. (2014); e-pub ahead of print.
10. Medicine HUFo. Trial of High-Dose Rifampin in Patients With TB (HIRIF) In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2000. Accessed 1 May 2015.
11. Savic, R.W. et al. Pharmacokinetic-pharmacodynamic analysis of rifapentine in patients during intensive phase treatment for tuberculosis from Tuberculosis Trial Consortium Studies 29 and 29X. In: 6th International Workshop on Pharmacology of Tuberculosis Drugs. Denver, CO; 2013.
12. Padjadjaran, U. High-dose rifampicin for the treatment of tuberculous meningitis: a dose-finding study (ReDEFINe). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). (2000). Accessed 1 May 2015. Identifier: NCT02169882.
13. Verbist, L. & Gyselen, A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am. Rev. Respir. Dis. 98, 923-932 (1968).
14. Rosenthal, I.M. et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56, 4331-4340 (2012).
15. van Ingen, J. et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin. Infect. Dis. 52, e194-199 (2011).
16. Kreis, B. et al. Two three-month treatment regimens for pulmonary tuberculosis. Bull. Int. Union Tuberc. 51, 71-75 (1976).
17. Peloquin, C. What is the 'right' dose of rifampin? Int. J. Tuberc. Lung Dis. 7, 3-5 (2003).
18. Mitnick, C.D., McGee, B. & Peloquin, C.A. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin. Pharmacother. 10, 381-401 (2009).
19. Ruslami, R. et al. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 51, 2546-2551 (2007).
20. Alsultan, A. & Peloquin, C.A. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 74, 839-854 (2014).
21. van Crevel, R. et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int. J. Tuberc. Lung Dis. 6, 497-502 (2002).
22. Kimerling, M.E. et al. Low serum antimycobacterial drug levels in non- HIV-infected tuberculosis patients. Chest. 113, 1178-1183 (1998).
23. Peloquin, C.A. et al. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41, 2670-2679 (1997).
24. Acocella, G.P., Marchetti, M., Baroni, G.C. & Nicolis, F.B. Kinetic studies on rifampicin I. Chemotherapy. 16, 356-370 (1971).
25. Nijland, H.M. et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin. Infect. Dis. 43, 848-854 (2006).
26. Chideya, S. et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48, 1685-1694 (2009).
27. Peloquin, C.A. Tuberculosis drug serum levels. Clin. Infect. Dis. 33, 584-585 (2001).
28. Burman, W.J., Gallicano, K. & Peloquin, C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40, 327-341 (2001).
29. Strolin Benedetti, M. & Dostert, P. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ. Health Perspect. 102(suppl. 9), 101-105 (1994).
30. Smythe, W. et al. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob. Agents Chemother. 56, 2091-2098 (2012).
31. Rosenthal, I.M., Zhang, M., Almeida, D., Grosset, J.H. & Nuermberger, E.L. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am. J. Respir. Crit. Care Med. 178, 989-993 (2008).
32. Dorman, S.E. et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J. Infect. Dis. 206, 1030-1040 (2012).
33. Dutta, N.K. et al. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob. Agents Chemother. 56, 3726-3731 (2012).
34. Mor, N., Simon, B., Mezo, N. & Heifets, L. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39, 2073-2077 (1995).
35. Egelund, E.F. et al. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 58, 4904-4910 (2014).
36. Reith, K. et al. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab. Dispos. 26, 732-738 (1998).
37. Weiner, M. et al. Pharmacokinetics of rifapentine at 600, 900, and 1, 200 mg during once-weekly tuberculosis therapy. Am. J. Respir. Crit. Care Med. 169, 1191-1197 (2004).
38. Savic, R.M. et al. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob. Agents Chemother. (2014); e-pub ahead of print.
39. Li, A.P. et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem. Biol. Interact. 107, 17-30 (1997).
40. Weiner, M. et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin. Infect. Dis. 41, 1343-1349 (2005).
41. Hafner, R. et al. Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. Antimicrob. Agents Chemother. 45, 1572-1577 (2001).
42. Timmins, G.S. & Deretic, V. Mechanisms of action of isoniazid. Mol. Microbiol. 62, 1220-1227 (2006).
43. Donald, P.R. et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 156, 895-900 (1997).
44. Jayaram, R. et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48, 2951-2957 (2004).
45. de Steenwinkel, J.E. et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 65, 2582-2589 (2010).
46. AHFS drug information. Bethesda, MD: American Society of Health- Systems Pharmacists; 2006.
47. Weiner, M. et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am. J. Respir. Crit. Care Med. 167, 1341-1347 (2003).
48. Kinzig-Schippers, M. et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49, 1733-1738 (2005).
49. Azuma, J. et al. NAT2 genotype guided regimen reduces isoniazidinduced liver injury and early treatment failure in the 6-month fourdrug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur. J. Clin. Pharmacol. 69, 1091-1101 (2013).
50. Primary Anti-TB Drug Resistance United States, 1993-2011. Centers for Disease Control. (2011). Accessed 1 May 2015.
51. Mikusova, K., Slayden, R.A., Besra, G.S. & Brennan, P.J. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob. Agents Chemother. 39, 2484-2489 (1995).
52. Zhu, M. et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int. J. Tuberc. Lung Dis. 8, 1360-1367 (2004).
53. Blumberg, H.M. et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603-662 (2003).
54. Jindani, A., Aber, V.R., Edwards, E.A. & Mitchison, D.A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121, 939-949 (1980).
55. Donomae, I. & Yamamoto, K. Clinical evaluation of ethambutol in pulmonary tuberculosis. Ann. N. Y. Acad. Sci. 135, 849-881 (1966).
56. Zimhony, O., Cox, J.S., Welch, J.T., Vilcheze, C. & Jacobs, W.R., Jr. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6, 1043-1047 (2000).
57. Donald, P.R., Maritz, J.S. & Diacon, A.H. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis. 92, 1-8 (2012).
58. Gumbo, T., Dona, C.S., Meek, C. & Leff, R. Pharmacokineticspharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 53, 3197-3204 (2009).
59. Chigutsa, E. et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob. Agents Chemother. 59, 38-345 (2015).
60. McDermott, W. et al. Pyrazinamide-isoniazid in tuberculosis. Am. Rev. Tuberc. 69, 319-333 (1954).
61. Pasipanodya, J.G. & Gumbo, T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob. Agents Chemother. 54, 2847-2854 (2010).
62. Rodriguez, J.C., Ruiz, M., Lopez, M. & Royo, G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents. 20, 464-467 (2002).
63. Peloquin, C.A. et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52, 852-857 (2008).
64. Weiner, M. et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob. Agents Chemother. 51, 2861-2866 (2007).
65. Nuermberger, E.L. et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170, 1131-1134 (2004).
66. Gillespie, S.H. et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577-1587 (2014).
67. Jawahar, M.S. et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 8, e67030 (2013).
68. Gumbo, T. et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190, 1642-1651 (2004).
69. Diacon, A.H. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med. 371, 723-732 (2014).
70. Diacon, A.H. et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 56, 3271-3276 (2012).
71. Skripconoka, V. et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur. Respir. J. 41, 1393-1400 (2013).
72. Gler, M.T. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 366, 2151-2160 (2012).
73. Diacon, A.H. et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 380, 986-993 (2012).
74. Yip, P.C., Kam, K.M., Lam, E.T., Chan, R.C. & Yew, W.W. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates. Int. J. Antimicrob. Agents. 42, 96-97 (2013).
75. Wallis, R.S. et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One. 9, e94462 (2014).